Medical cannabis in children: what we know about epilepsy, autism, and safety

Robust evidence supports purified CBD for specific refractory epilepsies in children, but most pediatric medical cannabis use involves artisanal CBD-rich products for epilepsy and autism, where evidence is more limited.

Aran, Adi et al.·Rambam Maimonides medical journal·2020·Moderate EvidenceReview
RTHC-02392ReviewModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Robust evidence exists only for pure CBD treating specific refractory epilepsies (Dravet, Lennox-Gastaut). In practice, artisanal CBD-rich cannabis products are being used for various epilepsy types and autism-related irritability. Other pediatric conditions being considered include Tourette syndrome and spasticity. Recreational cannabis use in youth is associated with serious adverse events, so medical use decisions should be made with caution.

Key Numbers

No specific pooled statistics. Review covered FDA-approved CBD (Epidiolex) and artisanal CBD-rich products.

How They Did This

Review summarizing current evidence for safety, tolerability, and efficacy of medical cannabis in children with epilepsy and autism spectrum disorder.

Why This Research Matters

Pediatric medical cannabis use is growing rapidly, outpacing the evidence base. Parents need clear guidance about what is proven versus experimental.

The Bigger Picture

The tension between standardized pure CBD (more evidence, more consistent) and whole-plant extracts (potential entourage effect, less consistency) is a central debate in pediatric medical cannabis.

What This Study Doesn't Tell Us

Review, not primary research. Limited evidence for conditions beyond specific refractory epilepsies. Artisanal product quality is variable.

Questions This Raises

  • ?Does the entourage effect provide additional benefit over pure CBD in children?
  • ?How should THC exposure be managed in developing brains?

Trust & Context

Key Stat:
Robust evidence only for pure CBD in specific epilepsies
Evidence Grade:
Comprehensive review with clear differentiation between evidence levels for different conditions.
Study Age:
2020 review.
Original Title:
Medical Cannabis in Children.
Published In:
Rambam Maimonides medical journal, 11(1) (2020)
Database ID:
RTHC-02392

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Is medical cannabis safe for children?

Pure CBD has a well-documented safety profile for specific epilepsies. THC-containing products pose more concerns in developing brains. Artisanal products vary in quality and consistency.

Does medical cannabis help children with autism?

Some families use CBD-rich cannabis for autism-related irritability, but the evidence is more limited than for epilepsy and decisions should be made cautiously.

Read More on RethinkTHC

Cite This Study

RTHC-02392·https://rethinkthc.com/research/RTHC-02392

APA

Aran, Adi; Cayam-Rand, Dalit. (2020). Medical Cannabis in Children.. Rambam Maimonides medical journal, 11(1). https://doi.org/10.5041/RMMJ.10386

MLA

Aran, Adi, et al. "Medical Cannabis in Children.." Rambam Maimonides medical journal, 2020. https://doi.org/10.5041/RMMJ.10386

RethinkTHC

RethinkTHC Research Database. "Medical Cannabis in Children." RTHC-02392. Retrieved from https://rethinkthc.com/research/aran-2020-medical-cannabis-in-children

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.